The following was reported to gore: on (b)(6) 2019, the patient underwent surgical treatment for the creation of a vascular access graft for hemodialysis with a gore-tex® stretch vascular graft.During the procedure anticoagulant / antiplatelet was used and the device was implanted and retained successfully.On (b)(6) 2019, an adverse event termed hematoma after the creation of humero-axillary prosthetic line was discovered and the primary relationship was recorded as procedure related.A reintervention in the form of a revision surgery was performed and the patient recovered without a sequelea.According to reports on (b)(6) 2020, another adverse event termed false aneurysm on the right prosthetic humero axillary line was recorded.The primary relationship was recorded as disease related and the patient recovered without a sequelea after an unspecified reintervention was performed.
|
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H3 code b20 and h6 : the device remains implanted in the patient.Therefore a device evaluation could not be performed.H6 code b14: a review of the manufacturing records indicated the lot met all pre-release manufacturing specifications w.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|